Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification

Leukemia Research

Volumn 32, Issue 3, 2008, Pages 514-516

  Cannella, Laura ^a   Breccia, Massimo ^a   Latagliata, Roberto ^a   Frustaci, Annamaria ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

BONE MARROW BIOPSY; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DISEASE CLASSIFICATION; FUSION GENE; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LETTER; MEDICAL INFORMATION; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MONOSOMY 7; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTORY ANEMIA; RETROSPECTIVE STUDY; SIDEROBLASTIC ANEMIA; THROMBOCYTE COUNT; THROMBOCYTOSIS; TRISOMY 8; WORLD HEALTH ORGANIZATION;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; PROGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 39749120756     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.07.004     Document Type: Letter

References (15)

1. Jaffe E., Harris N., Stein H., and Vardiman J. The World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon
2. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 7 (2002) 2292-2302
3. Bain B., Vardiman J., Imbert M., and Pierre R. Myelodysplastic/myeloproliferative disease, unclassifiable. In: Jaffe E., Harris N., Stein H., and Vardiman J. (Eds). The World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon 58-59
4. Shaw G.R. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 131 2 (2005) 180-184
5. Wang S.A., Hasserjian R.P., Loew J.M., Sechman E.V., Jones D., Hao S., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 20 9 (2006) 1641-1644
6. Cabello A.I., Collado R., Ruiz M.A., Martinez J., Navarro I., Ferrer R., et al. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. Leukemia Res 29 4 (2005) 365-370
7. Atallah E., Kantarjian H., Cortes J., Pierce S., Estey E., Garcia-Manero G., et al. Clinical features and prognosis of patients with myelodysplastic/myeloproliferative syndrome-unclassified (MDS/MPD-U): refractory anemia with ringed sideroblasts with thrombocytosis (RARS-T) is a favorable prognostic subgroup. ASH Annu. Meet. Abstr. 108 11 (2006) 2612
8. Szpurka H., Tiu R., Murugesan G., Aboudola S., Hsi E.D., Theil K.S., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108 7 (2006) 2173-2181
9. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 2 (1982) 189-199
10. Mufti G., Stevens J., Oscier D., Hamblin T., and Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59 (1985) 425-433
11. Sanz G., Sanz M., Vallespi T., Canizo M., Torrabadella M., Garcia S., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74 1 (1989) 395-408
12. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 6 (1997) 2079-2088
13. Worsley A., Oscier D.G., Stevens J., Darlow S., Figes A., Mufti G.J., et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 68 1 (1988) 17-21
14. 9/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 109 3 (2007) 1334-1335
15. Remacha A., Nomdedeu J., Puget G., Estivill C., Sarda M., Canals C., et al. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 91 5 (2006) 719